\-\ Texto\\:\\ \ \(0\)\
\-\ normal\\ physical\\ examination\\.\ \(0\)\
\-\ labs\\:\ \(4\)\
\-\ hbsag\\:\\ nr\ \(0\)\
\-\ hcv\\ ab\\:\\ nr\ \(0\)\
\-\ estradiol\\:\\ 33ng\\/dl\ \(0\)\
\-\ prolactin\\:\\ 27\\.46\\ ng\\/dl\ \(0\)\
\-\ ft4\\:\\ 0\\.96\\ ng\\/dl\ \(0\)\
\-\ lh\\:\\ 2\\.62\\ miu\\/ml\ \(0\)\
\-\ fsh\\:\\ 5\\.1\\ miu\\/ml\ \(0\)\
\-\ pap\\ smear\\:\\ negatice\\ for\\ neoplastic\\ cells\\ with\\ indication\\ of\\ vaginosis\ \(0\)\
\-\ small\\ outpouchings\\ in\\ the\\ right\\ fallopian\\ tube\\ area\\ with\\ no\\ evidence\\ of\\ patency\\ or\\ spillage\\ of\\ contrast\\ into\\ the\\ peritoneal\\ cavity\\.\ \(0\)\
\-\ salpingitis\\ isthmica\\ nodosa\ \(0\)\
\-\ tuberculous\\ salpingitis\\.\ \(0\)\
\-\ tubal\\ adenomyosis\ \(0\)\
\-\ 34\\ year\\-old\\ female\\ with\\ \\ history\\ of\\ 2\\ previous\\ ectopic\\ pregnancies\\ treated\\ with\\ methotrexate\\ medical\\ therapy\\ when\\ it\\ occurred\\ on\\ the\\ left\\ side\\ and\\ with\\ partial\\ salpingectomy\\ when\\ it\\ occurred\\ on\\ the\\ right\\ side\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ nr\\:\\ 0\\.26753329437898965\ \(0\)\
\-\ salpingitis\\:\\ 0\\.26753329437898965\ \(0\)\
\-\ occurred\\:\\ 0\\.18736754252074353\ \(0\)\
\-\ negatice\\:\\ 0\\.1550605586686338\ \(0\)\
\-\ vaginosis\\:\\ 0\\.1550605586686338\ \(0\)\
\-\ isthmica\\:\\ 0\\.14327874911962907\ \(0\)\
\-\ hbsag\\:\\ 0\\.13948585361719223\ \(0\)\
\-\ hcv\\:\\ 0\\.13948585361719223\ \(0\)\
\-\ estradiol\\:\\ 0\\.13948585361719223\ \(0\)\
\-\ side\\:\\ 0\\.13396578229171985\ \(0\)\
\-\ fsh\\:\\ 0\\.13376664718949483\ \(0\)\
\-\ lh\\:\\ 0\\.13149693957062433\ \(0\)\
\-\ salpingectomy\\:\\ 0\\.13149693957062433\ \(0\)\
\-\ pap\\:\\ 0\\.12460502279381812\ \(0\)\
\-\ outpouchings\\:\\ 0\\.12460502279381812\ \(0\)\
\-\ nodosa\\:\\ 0\\.12460502279381812\ \(0\)\
\-\ adenomyosis\\:\\ 0\\.12324449221092743\ \(0\)\
\-\ spillage\\:\\ 0\\.12198483764049008\ \(0\)\
\-\ prolactin\\:\\ 0\\.11971513002161958\ \(0\)\
\-\ smear\\:\\ 0\\.11971513002161958\ \(0\)\
\-\ pregnancies\\:\\ 0\\.1177131060170119\ \(0\)\
\-\ when\\:\\ 0\\.11713921095229538\ \(0\)\
\-\ patency\\:\\ 0\\.11679409527626894\ \(0\)\
\-\ tuberculous\\:\\ 0\\.11592223451918277\ \(0\)\
\-\ tubal\\:\\ 0\\.11509292086368386\ \(0\)\
\-\ ft4\\:\\ 0\\.11282321324481337\ \(0\)\
\-\ ab\\:\\ 0\\.11212933901674593\ \(0\)\
\-\ methotrexate\\:\\ 0\\.10903031774237655\ \(0\)\
\-\ indication\\:\\ 0\\.10793332047261485\ \(0\)\
\-\ fallopian\\:\\ 0\\.10213840096557034\ \(0\)\
\-\ it\\:\\ 0\\.09926520034309666\ \(0\)\
\-\ with\\:\\ 0\\.09493015215760703\ \(0\)\
\-\ peritoneal\\:\\ 0\\.09112934076625676\ \(0\)\
\-\ neoplastic\\:\\ 0\\.08961745069514293\ \(0\)\
\-\ ectopic\\:\\ 0\\.0857523786162761\ \(0\)\
\-\ 34\\:\\ 0\\.08450301624004303\ \(0\)\
\-\ cavity\\:\\ 0\\.08005376281279146\ \(0\)\
\-\ tube\\:\\ 0\\.07747778459779915\ \(0\)\
\-\ the\\:\\ 0\\.07738833808603582\ \(0\)\
\-\ of\\:\\ 0\\.07589877222776521\ \(0\)\
\-\ cells\\:\\ 0\\.0747065090433293\ \(0\)\
\-\ partial\\:\\ 0\\.0747065090433293\ \(0\)\
\-\ previous\\:\\ 0\\.07326517497552403\ \(0\)\
\-\ labs\\:\\ 0\\.06717495599402501\ \(0\)\
\-\ right\\:\\ 0\\.0642926737724947\ \(0\)\
\-\ area\\:\\ 0\\.06281225658233737\ \(0\)\
\-\ examination\\:\\ 0\\.06204531935724003\ \(0\)\
\-\ medical\\:\\ 0\\.061622121774286956\ \(0\)\
\-\ treated\\:\\ 0\\.06037989166279124\ \(0\)\
\-\ on\\:\\ 0\\.058567323599812024\ \(0\)\
\-\ therapy\\:\\ 0\\.05570995598425684\ \(0\)\
\-\ evidence\\:\\ 0\\.05503478689873167\ \(0\)\
\-\ physical\\:\\ 0\\.05257407696170686\ \(0\)\
\-\ into\\:\\ 0\\.05154240326947478\ \(0\)\
\-\ small\\:\\ 0\\.05001536586529203\ \(0\)\
\-\ contrast\\:\\ 0\\.04711100901976747\ \(0\)\
\-\ female\\:\\ 0\\.046787795927142946\ \(0\)\
\-\ normal\\:\\ 0\\.03958822263891315\ \(0\)\
\-\ history\\:\\ 0\\.03704443113421854\ \(0\)\
\-\ or\\:\\ 0\\.03373074677203362\ \(0\)\
\-\ left\\:\\ 0\\.03307525824175839\ \(0\)\
\-\ no\\:\\ 0\\.03153037217339254\ \(0\)\
\-\ for\\:\\ 0\\.02938790964712639\ \(0\)\
\-\ in\\:\\ 0\\.024120565091498847\ \(0\)\
\-\ and\\:\\ 0\\.020035649953545242\ \(0\)\
